Pair page
CJC-1295 with HGH Fragment 176-191
Mechanism-tag overlap and published literature for CJC-1295 and HGH Fragment 176-191, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrhgrowth-hormone-releasing-hormone-analog
growth-hormone-c-terminal-fragment
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying CJC-1295 and HGH Fragment 176-191 have published these mechanism-level observations. Not a co-administration recommendation.
Full GH-axis stimulation stack for body composition: GH secretagogue (CJC-1295 + ipamorelin) drives endogenous GH and IGF-1 for recovery and lean mass, while HGH Fragment 176-191 provides a parallel lipolytic signal without adding to GH receptor stimulation. Rationale is mechanism separation: one drives GH-axis, the other drives fat-specific lipolysis.
Quick facts
CJC-1295
HGH Fragment 176-191
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2006 | CJC-1295 | aidsmap. Lipodystrophy study halted after patient death. July 2006. (Reports the ConjuChem Phase 2 CJC-1295 trial halt.) | human trial, Phase 2 |
| 2010 | CJC-1295 | Alexopoulou O, Abs R, Maiter D. Treatment of adult growth hormone deficiency: who, why and how? A review. Acta Clin Belg. 2010;65(1):13-22. PMID: 20373593. PMID 20373593 | human study |
| 2009 | CJC-1295 | Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19540144. PMID 19540144 | human study |
| 2006 | CJC-1295 | Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805… PMID 16352683 | human study |
| 2006 | CJC-1295 | Abla AA, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E… PMID 16835399 | preclinical, in vivo |
| 2005 | CJC-1295 | Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.… PMID 15817669 | preclinical, in vivo |
| 2005 | CJC-1295 | Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2005;289(5):E762-E767. | preclinical, in vivo |
| 2020 | CJC-1295 | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 1995 | CJC-1295 | Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA. 1995;92(10):4872-4876. PMID: 7761412. (Parent work on tetrasubstituted GHRH analogs.) PMID 7761412 | mechanism / discovery |
| 2023 | CJC-1295 | Alwatban MZ, Al-Lohedan HA. A review of CJC-1295 as a GHRH analog: Pharmacology and clinical relevance. Drug Des Devel Ther. 2023 (review series). | review |
| 2026 | CJC-1295 | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | CJC-1295 | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2013 | HGH Fragment 176-191 | Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. (AOD-9604 human tolerability data.) | human study |
| 2001 | HGH Fragment 176-191 | Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 117132… PMID 11713212 | preclinical, in vivo |
| 2000 | HGH Fragment 176-191 | Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11146361. (AOD-9604 preclinical metabolic characterization.) PMID 11146361 | preclinical, in vivo |
| 2000 | HGH Fragment 176-191 | Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PMID: 10913053. (Oral bioavailability and lipid-metabolism effects of the GH frag… PMID 10913053 | pharmacology |
| — | HGH Fragment 176-191 | U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Category 2 list. FDA.gov. | regulatory / registry |
| 1999 | HGH Fragment 176-191 | Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of doping with human growth hormone. Lancet. 1999;353(9156):895. PMID: 10093986. (Context for GH-family detection.) PMID 10093986 | research article |
| 1988 | HGH Fragment 176-191 | Salem MA. A possible direct lipolytic effect of growth hormone. Proc Soc Exp Biol Med. 1988;187(1):1-6. PMID: 3340595. (Mechanistic context for GH lipolytic activity.) PMID 3340595 | research article |
| 1981 | HGH Fragment 176-191 | Rudman D, Kutner MH, Blackston RD, Cushman RA, Bain RP, Patterson JH. Children with normal-variant short stature: treatment with human growth hormone for six months. N Engl J Med. 1981;305(3):123-131. PMID: 7242610. (Reference for full-length GH effects, highlighting the differe… PMID 7242610 | research article |
| 1978 | HGH Fragment 176-191 | Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-E526. PMID: 645887. (Early structural dissection of GH C-terminal activity.) PMID 645887 | research article |
Related pair pages
More research context
Frequently asked
Have CJC-1295 and HGH Fragment 176-191 been studied together?
Researchers have published mechanistic-level co-administration discussion of CJC-1295 and HGH Fragment 176-191. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do CJC-1295 and HGH Fragment 176-191 share?
CJC-1295 and HGH Fragment 176-191 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of CJC-1295 and HGH Fragment 176-191?
CJC-1295: Not approved. HGH Fragment 176-191: Not approved; Category 2. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on CJC-1295 and HGH Fragment 176-191?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the CJC-1295 profile and the HGH Fragment 176-191 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026